- Home
- NAGE
as 11-25-2025 3:40pm EST
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | LOS ANGELES |
| Market Cap: | 766.4M | IPO Year: | N/A |
| Target Price: | $16.33 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.23 | EPS Growth: | 1093.81 |
| 52 Week Low/High: | $5.16 - $14.69 | Next Earning Date: | 11-04-2025 |
| Revenue: | $124,709,000 | Revenue Growth: | 36.04% |
| Revenue Growth (this year): | 29.51% | Revenue Growth (next year): | 20.55% |
Latest Niagen Bioscience Inc. Common Stock News
NAGE Breaking Stock News: Dive into NAGE Ticker-Specific Updates for Smart Investing
MT Newswires
12 days ago
Correction: Niagen Says Long COVID Trial Exploring Supplement Failed to Show 'Statistically Significant Differences' in Meeting Endpoints Versus Placebo Groups
Business Wire
12 days ago
Niagen Bioscience Launches Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. Featuring Niagen® (Patented Nicotinamide Riboside)
Simply Wall St.
13 days ago
Shareholders Can Be Confident That Niagen Bioscience's (NASDAQ:NAGE) Earnings Are High Quality
MT Newswires
13 days ago
Niagen Bioscience Says Supplement Failed to Meet Endpoints in Study of Long COVID-19 Patients
Business Wire
13 days ago
Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID
Simply Wall St.
14 days ago
3 Growth Companies With High Insider Ownership And Up To 26% Revenue Growth
Simply Wall St.
19 days ago
Niagen Bioscience, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
MT Newswires
19 days ago
Niagen Bioscience Approves $10 Million Stock Buyback Program
Compare NAGE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NAGE Niagen Bioscience Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.